Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

1.030 -0.030 (-2.83%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services
From bioAffinity Technologies
Via Business Wire
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents Research Findings at CYTO 2023
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports First Quarter 2023 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Ring Nasdaq Closing Bell Today
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.